Ralliant Corporation (NYSE:RAL) Given Average Rating of “Moderate Buy” by Analysts

Ralliant Corporation (NYSE:RAL) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $67.30.

RAL has been the subject of several analyst reports. Wall Street Zen cut shares of Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Citigroup raised their target price on shares of Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Zacks Research raised shares of Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Truist Financial reissued a “buy” rating and issued a $68.00 target price (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Finally, TD Cowen raised their target price on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 20th.

Ralliant Price Performance

Shares of Ralliant stock opened at $63.66 on Friday. Ralliant has a twelve month low of $37.27 and a twelve month high of $64.16. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The company has a 50-day simple moving average of $51.63 and a two-hundred day simple moving average of $49.45. The stock has a market capitalization of $7.13 billion and a price-to-earnings ratio of -5.82.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business had revenue of $534.60 million during the quarter. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts forecast that Ralliant will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Hedge Funds Weigh In On Ralliant

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Ralliant by 10.7% in the 3rd quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock valued at $637,995,000 after buying an additional 1,415,327 shares during the period. Dodge & Cox grew its holdings in shares of Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock valued at $621,849,000 after purchasing an additional 1,434,376 shares during the last quarter. Viking Global Investors LP bought a new stake in shares of Ralliant during the 2nd quarter valued at approximately $257,200,000. Millennium Management LLC grew its holdings in shares of Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after purchasing an additional 3,147,660 shares during the last quarter. Finally, State Street Corp bought a new stake in shares of Ralliant during the 2nd quarter valued at approximately $213,096,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.